2,914 material Form 8-K filings that 2,352 companies we cover made with the SEC in August 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
On August 27, 2026, Digi International entered into an amended and restated $350 million senior secured revolving credit agreement with BMO Bank N.A. as administrative agent. The new facility replaces a $250 million agreement dated December 7, 2023, which Digi paid off and terminated, and it matures on August 27, 2031. The company says the expanded capacity and lower pricing give it more financial flexibility for acquisitions, though the filing does not report any earnings or cash flow figures.
$350 million senior secured revolving facility, with an uncommitted accordion of the greater of $130 million or 100% of trailing four-quarter EBITDA, maturing August 27, 2031.
Replaces the $250 million revolving credit agreement dated December 7, 2023, which was paid off and terminated on August 27, 2026.
Term SOFR margins range from 1.25% to 2.625%, compared with 135 to 310 basis points under the prior facility, according to the press release.
Maximum total net leverage covenant increased from 3.0x to 3.50x; minimum interest coverage ratio of 3.00x is unchanged.
Americold closed its joint venture with EQT's Active Core Infrastructure fund on August 31, 2026, contributing 12 cold storage facilities valued at more than $1.3 billion. Americold received approximately $1.1 billion in net cash proceeds, which it intends to use to repay outstanding debt, and it will hold a 30% stake and serve as day-to-day manager. Shareholders face a capped contingent income support obligation of up to $70 million over the term.
Joint venture closed August 31, 2026; EQT holds 70% and Americold holds 30% of Americold-EQT Cold Storage Partnership, LLC
Approximately $1.1 billion in net cash proceeds, expected to be used to repay outstanding indebtedness
Income support arrangement capped at up to $70 million over the 10-year term
Joint venture obtained mortgage financing of up to $863.5 million, of which $845.5 million was drawn at closing
Array Technologies said it completed its acquisition of Affordable Wire Management, LLC (AWM), a provider of wire management and balance-of-system products for solar and energy storage projects, on August 31, 2026. Buyer paid cash consideration of approximately $165 million, net of customary adjustments and subject to final post-closing settlement. The company expects the deal to be at least high single digit accretive to Adjusted EPS in the first year before synergies.
Acquisition of AWM completed August 31, 2026 under a purchase agreement dated July 16, 2026
Cash consideration of approximately $165 million, subject to final post-closing settlement
Expected to be at least high single digit accretive to Adjusted EPS in the first year before synergies
Kevin G. Hostetler is CEO of Array; Scott Rand and Dan Smith, AWM co-founders, join as leaders of the combined business
PMV Pharmaceuticals reported updated interim ovarian cancer data for rezatapopt from the Phase 2 pivotal portion of its PYNNACLE trial, with a 46% overall response rate among 76 evaluable patients. The company said recent FDA feedback supports submitting a new drug application for accelerated approval in platinum-resistant or refractory ovarian cancer in the first quarter of 2027, which sets a timeline for shareholders to track.
Overall response rate of 46% (35 of 76 patients) as of a May 14, 2026 data cutoff; median duration of response was 10.0 months
Company anticipates submitting an NDA for accelerated approval in the first quarter of 2027
Discontinuation due to treatment-related adverse events was 5%; full update on all Phase 2 cohorts planned for the fourth quarter of 2026 at a medical conference
BOK Financial filed an August 2026 investor presentation furnished under Regulation FD, which includes second-quarter 2026 results and an updated full-year 2026 outlook dated 07/21/26. Net income and diluted earnings per share rose from the prior quarter and the prior year, and the company reported no provision for credit losses in the quarter.
Q2 2026 net income was $176.5 million, or $2.92 per diluted share, versus $155.8 million, or $2.58, in Q1 2026 and $140.0 million, or $2.19, in Q2 2025.
Period-end loans grew $896 million, or 3.4% sequentially, to $27.1 billion; net charge-offs were $500 thousand.
The 2026 outlook as of 07/21/26 projects net interest income of $1.42 to $1.45 billion and fees and commissions of $820 to $845 million.
The company expects a 2026 efficiency ratio of about 62%, compared with 65.1% in 2025.
Cadrenal Therapeutics said that at a Type D meeting with the U.S. Food and Drug Administration held July 28, 2026, the company and the FDA aligned on key aspects of the protocol and Statistical Analysis Plan for a Phase 3 registrational study of CAD-1005 in heparin-induced thrombocytopenia (HIT). The filing says the agreement sets the primary endpoint definition and the use of a placebo control, which the company says clarifies the regulatory path, but it does not disclose financial results, costs, or a trial start date.
Type D meeting with the FDA held July 28, 2026; the company announced the feedback on August 31, 2026.
Primary endpoint measures the proportion of Serotonin Release Assay-positive participants with adjudicated new or worsening composite thromboembolic events through Day 14 or hospital discharge.
The FDA agreed to a placebo control, with standard anticoagulation therapeutics in both the CAD-1005 and placebo arms.
The company states that approximately 50,000 patients in the U.S. have acute HIT each year.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.